CareDx Inc. to Present New Allosure Data; at American Society of Transplant Surgeons Winter Symposium
January 10, 2019 at 06:08 am IST
Share
CareDx Inc. announced that the company will be presenting data highlighting the AlloSure test and hosting a lunch symposium at the American Society of Transplant Surgeons (ASTS) 19th Annual Winter Symposium in Miami, Florida, from 10th - 13th January, 2019 . The two keynote speakers, Steve Potter, M.D., transplant surgeon at Baylor, Scott &White Health, and Stanley Jordan, M.D., Director of the Nephrology Division at Cedars-Sinai Comprehensive Transplant Center, will share their experiences using AlloSure to assist in management of post-transplant patients. Together with Sham Dholakia, M.D., DPhil, Medical Director, CareDx Inc., they will present examples of AlloSure patient cases, discuss best ways to surveil kidney transplant recipients for graft health, and to personalize their care. In addition, an abstract titled "Donor-derived cell-free DNA in renal transplant recipients with delayed graft function" will be presented during the ASTS poster session on January 10, from 5:45 - 7:15 pm. This study demonstrates that many patients with delayed graft function (DGF) exhibit elevated AlloSure levels immediately following their transplant, and for up to two years. Additional information and resources on CareDx Inc. and CareDx products will also be available at the CareDx booth #23/24.
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
CAREDX, INC 
